GNFT

GENFIT S.A.

5.49 USD
+1.27 (+30.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

GENFIT S.A. stock is up 41.49% since 30 days ago. The next earnings date is Sep 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 July’s closed higher than June.

About GENFIT S.A.

Genfit S.A. discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. Elafibranor is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test.